MedTrace Logo

Trial of Zinc and HIV Progression in Children

NCT00446758 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 440

Last updated 2012-09-14

No results posted yet for this study

Summary

To examine whether daily oral zinc supplementation to HIV-infected Tanzanian preschool children reduces diarrheal and respiratory morbidity, delays HIV disease progression, and improves growth.

Conditions

  • HIV Infections

Interventions

DIETARY_SUPPLEMENT

Zinc

zinc effervescent tablets: 6.25mg to infants ≤12 months and 12.5 mg to children \> 12 months.

Sponsors & Collaborators

  • Thrasher Research Fund

    collaborator OTHER

  • Muhimbili University of Health and Allied Sciences

    collaborator OTHER

  • Harvard School of Public Health (HSPH)

    lead OTHER

Principal Investigators

  • Eduardo Villamor, MD, DrPH · Harvard School of Public Health (HSPH)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Weeks
Max Age
60 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • Tanzania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00446758 on ClinicalTrials.gov